Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSGC-CBP30
说明： Potent CBP/p300 BRD inhibitor
化学名： 2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole
纯度： ≥98% (HPLC)
生物活性 for SGC-CBP30
SGC-CBP30 is a potent CBP/p300 bromodomain (BRD) inhibitor (Kd values are 21 and 32 nM for CBP and p300 BRDs respectively). Exhibits 40-fold and 250-fold selectivity for CBP over the first BRD of BRD4 (BRD4(1)) and BRD4(2) respectively. Accelerates FRAP recovery in cells at a concentration of 1 μM. SGC-CBP30 can be used in protocols for the chemical reprogramming of somatic cells to iPSCs.
许可信息
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the SGC-CBP30 probe summary on the SGC website.
External Portal Information for SGC-CBP30
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of SGC-CBP30 is reviewed on the chemical probes website.
化合物库 for SGC-CBP30
SGC-CBP30 is also offered as part of the Tocriscreen Epigenetics Library. 了解 Tocris 化合物库的更多信息。
技术数据 for SGC-CBP30
| 分子量 | 509.04 |
| 公式 | C28H33ClN4O3 |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 1613695-14-9 |
| PubChem ID | 72201027 |
| InChI Key | GEPYBHCJBORHCE-SFHVURJKSA-N |
| Smiles | CC1=C(C(C)=NO1)C2=CC=C3C(N=C(CCC4=CC(Cl)=C(OC)C=C4)N3C[C@@H](N5CCOCC5)C)=C2 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for SGC-CBP30
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 100 | ||
| ethanol | 100 |
制备储备液 for SGC-CBP30
以下数据基于产品分子量 509.04。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.96 mL | 9.82 mL | 19.64 mL |
| 5 mM | 0.39 mL | 1.96 mL | 3.93 mL |
| 10 mM | 0.2 mL | 0.98 mL | 1.96 mL |
| 50 mM | 0.04 mL | 0.2 mL | 0.39 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for SGC-CBP30
参考文献 for SGC-CBP30
参考文献是支持产品生物活性的出版物。
Gallenkamp et al (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9 438 PMID: 24497428
Hay et al (2014) Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J.Am.Chem.Soc. 136 9308 PMID: 24946055
Hammitzsch et al (2015) CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc.Natl.Acad.Sci.U.S.A. 112 10768 PMID: 26261308
Guan et al (2022) Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 605 325 PMID: 35418683
If you know of a relevant reference for SGC-CBP30, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: SGC-CBP30, SGC-CBP30 supplier, SGCCBP30, CREBBP, CBP, EP300, p300, bromodomains, inhibitors, inhibits, chemical, probes, epigenetics, SGC, potent, selective, active, in, cells, permeable, structural, genomics, consortium, induced, pluripotent, stem, reprogramming, iPSC, Bromodomains, Histone, Acetyltransferases, Stem, Cell, Reprogramming, 4889, Tocris Bioscience
4 篇 SGC-CBP30 的引用文献
引用文献是使用了 Tocris 产品的出版物。 SGC-CBP30 的部分引用包括：
Christopher J et al (2022) Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Cancer Res 82 3375-3393 PMID: 35819261
Koh et al (2018) A conserved enhancer regulates Il9 expression in multiple lineages. Nat Commun 9 4803 PMID: 30442929
Walter et al (2021) A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma. Front Cell Dev Biol 9 612518 PMID: 33968920
Laurent et al (2021) Network-Based Integration of Multi-Omics Data Identifies the Determinants of miR-491-5p Effects. Cancers (Basel) 13 PMID: 34439123
您是否知道使用了 Tocris SGC-CBP30 的优秀论文？ 请告知我们.
SGC-CBP30 的评论
平均评分: 5 (Based on 1 Review.)
Have you used SGC-CBP30?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
p300 inhibition.
By
Anonymous on 10/31/2022
分析类型： In Vitro
种属： Mouse
细胞系/组织： 293T
Used to inhibit p300 and downstream genes. We treated 293 cells with CBP30 and then detected p300 staining with IF. Figure: Green channel is p300 in nucleus
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Stem Cell Research Product Guide
This product guide provides a background to the use of small molecules in stem cell research and lists over 200 products for use in:
- Self-renewal and Maintenance
- Differentiation
- Reprogramming
- Organoid Generation
- GMP and Ancillary Material Grade Products
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.